Cite
HARVARD Citation
Long, G. et al. (2015). A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].